Why the study?
Does substituting nafamostat mesilate for heparin prevent recurrence of cardiac tamponade secondary to hemorrhagic pericarditis in patients undergoing continuous hemofiltration for renal failure?
Does substituting nafamostat mesilate for heparin prevent recurrence of cardiac tamponade secondary to hemorrhagic pericarditis in patients undergoing continuous hemofiltration for renal failure?
Nafamostat mesilate may be a safer anticoagulant alternative to heparin to prevent hemorrhagic pericarditis and cardiac tamponade during continuous hemofiltration in renal failure.
Answers are grounded in this paper and cite their sources.
Nafamostat substitution may avoid heparin-associated tamponade recurrence in hemofiltration; hypothesis-generating and should not yet change practice.
Cardiac tamponade secondary to hemorrhagic pericarditis during continuous hemofiltration (CHF) for renal failure is reported. Cardiac tamponade developed while heparin was being used as an anticoagulant and did not recur when nafamostat mesilate was substituted. The role of the anticoagulant in the etiology of hemorrhagic pericarditis in dialysis patients is discussed.
No takes yet. Share an insight, caveat, or question.
Hiraide et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: